Gilead is aggressively scaling access to its revolutionary twice-yearly HIV prevention drug, lenacapivir, in sub-Saharan Africa through a no-profit, voluntary licensing model with partners like PEPFAR and the Global Fund.
The company is strategically diversifying beyond its core virology focus, making acquisitions in oncology and autoimmune diseases to build a robust pipeline in areas like cell therapy and antibody-drug conjugates.
Gilead is integrating artificial intelligence to accelerate drug discovery, aiming to reduce the typical decade-long process to six to eight years, thereby increasing the pace of innovation.
The company is actively engaging in US healthcare policy debates, advocating for reforms that lower patient out-of-pocket costs by addressing inefficiencies in the supply chain, where intermediaries capture 50% of every dollar spent on medicine.
8 quotes
Concerns Raised
The extremely high failure rate (99%) inherent in scientific research and drug discovery.
The 2-3 year timeline required for generic manufacturers to scale up production of lenacapivir.
The inefficiency of the U.S. healthcare system, where 50% of drug spending goes to intermediaries.
The challenge of balancing drug affordability with the need to preserve the ecosystem that fosters innovation.
Opportunities Identified
The potential to end the HIV epidemic within a generation using highly effective, long-acting prevention like lenacapivir.
Achieving curative responses in cancers like large B-cell lymphoma through advanced cell therapies.
Utilizing AI to significantly reduce drug discovery timelines from a decade down to 6-8 years.
The scientific concept of an 'immune reset' could potentially eradicate a host of autoimmune diseases.